Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo
- 9.5k Downloads
Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post-menopausal patients show anti-tumour benefit with ZOL whereas pre-menopausal patients do not. Here we have developed in vivo models of spontaneous ER+ve breast cancer metastasis to bone and investigated the effects of ZOL and oestrogen on tumour cell dissemination and growth. ER+ve (MCF7, T47D) or ER−ve (MDA-MB-231) cells were administered by inter-mammary or inter-cardiac injection into female nude mice ± estradiol. Mice were administered saline or 100 μg/kg ZOL weekly. Tumour growth, dissemination of tumour cells in blood, bone and bone turnover were monitored by luciferase imaging, histology, flow cytometry, two-photon microscopy, micro-CT and TRAP/P1NP ELISA. Estradiol induced metastasis of ER+ve cells to bone in 80–100 % of animals whereas bone metastases from ER−ve cells were unaffected. Administration of ZOL had no effect on tumour growth in the fat pad but significantly inhibited dissemination of ER+ve tumour cells to bone and frequency of bone metastasis. Estradiol and ZOL increased bone volume via different mechanisms: Estradiol increased activity of bone forming osteoblasts whereas administration of ZOL to estradiol supplemented mice decreased osteoclast activity and returned osteoblast activity to levels comparable to that of saline treated mice. ER−ve cells require increased osteoclast activity to grow in bone whereas ER+ve cells do not. Zol does not affect ER+ve tumour growth in soft tissue, however, inhibition of bone turnover by ZOL reduced dissemination and growth of ER+ve breast cancer cells in bone.
KeywordsER+ve Breast cancer Bone metastasis Zoledronic acid Estradiol
Oestrogen receptor positive breast cancer accounts for approximately 70 % of primary breast malignancies. The development of targeted hormonal and biological therapies have resulted in significant increases in survival, however progression to metastasis remains a substantial clinical problem. Around 65–70 % of cancers that metastasise to bone are ER+ve and this condition remains incurable . Due to the lack of clinically relevant models for ER+ve breast cancer bone metastasis the vast majority of pre-clinical studies have used hormone receptor negative cell lines to investigate breast cancer dissemination and growth in bone [reviewed in 2 and 3]. We have established in vivo models of spontaneous bone metastasis from ER+ve MCF7 and T47D cells grown in mouse mammary fat pads. These new models have enabled us, for the first time, to investigate some of the fundamental steps of bone metastasis following inoculation of cell lines into hind mammary fat pads, including growth at the primary site, tumour cell dissemination into the circulation and colonisation and growth in the bone microenvironment. We are now using these models to investigate the effects of bone targeted therapies on spontaneous bone metastasis of ER+ve xenografts.
There is increasing clinical and pre-clinical evidence supporting anti-tumour effects of the anti-resorptive agent zoledronic acid (ZOL) in hormone receptor negative breast cancer, but the effects on ER+ve breast cancers remain to be elucidated. Recent clinical trials suggest that menopausal status, rather than the hormone receptor status of the tumour, determines the anti-cancer efficiency of ZOL. The AZURE (Does Adjuvant zoledronic acid reduce Recurrence in stage II/III breast cancer?) trial  study investigated the use of adjuvant ZOL alongside chemotherapy in women with high risk of breast cancer recurrence. 3360 women were randomised to receive either placebo or intensive treatment with ZOL, in addition to standard therapy. Approximately 78 % of patients in each group had ER+ve tumours  and there was no correlation between hormone receptor status, disease free survival (DFS) or risk of death (ROD). In contrast, women who were postmenopausal for at least 5-years before entering the trial had a significantly increased disease free survival (25 %) and reduced risk of death from any cause (26 %) . These data were confirmed in the ABCSG-12 trial that showed increased DFS in women more than age 40 who received ZOL. However the ABCSC-12 study also presented evidence indicating that adjuvant use of ZOL improves the outcome of pre-menopausal patients with ER+ve tumours , although patients in this trial received goserelin, a superantagonist of oestrogen, whereas participants in the AZURE study did not.
The differences in anti-tumour effects of ZOL between pre-menopausal and post-menopausal patients with bone metastasis are likely to be influenced by the regulation of bone turnover by oestrogens. Oestrogen has profound effects on bone by inhibiting osteoclastogenesis and promoting osteoclast apoptosis via direct actions on osteoclasts and their precursors [8, 9, 10, 11, 12, 13]. In addition, oestrogens act on cells of the osteoblast lineage to prevent production of osteoclastigenic cytokines as well as inhibiting osteoclast apoptosis [10, 11, 12, 13]. ZOL also exerts pro-apoptotic effects on osteoclasts through inhibition of key enzymes in the mevalonate pathway, ultimately preventing the release of bone derived factors that may stimulate tumour growth . In contrast to oestrogen, administration of ZOL also reduces the number and activity of bone forming osteoblasts . It is therefore possible that ZOL may be a more effective anti-tumour agent in a low oestrogen bone microenvironment due to its ability to inhibit the increased activity of osteoclasts observed under these conditions.
We have recently used a mouse model that mimics the pre- and post-menopausal bone microenvironment to establish the effects of anti-resorptive agents on ER−ve MDA-MB-231 breast tumour growth in bone. In this model, reduced circulating oestrogen caused by ovariectomy resulted in increased osteoclastic bone resorption that triggered the growth of dormant disseminated tumour cells to form overt tumours in bone. Administration of ZOL, or the specific osteoclast inhibitor OPG-Fc, prevented ovariectomy-induced stimulation of ER−ve tumour growth in bone, providing evidence that this process is driven by osteoclast mediated mechanisms [16, 17]. Interestingly, injection of ER+ve MCF7 cells into mice with high osteoclast activity did not induce tumour growth in bone . We do not know if absence of tumour growth under these conditions was due to ER+ve tumour cells requiring oestrogen for growth and/or if different mechanisms are responsible for ER+ve and ER−ve breast cancer growth in bone.
In the current study we have investigated the effects of high levels of oestrogen on ER+ve tumour growth and spontaneous metastasis to bone, as well as on the ability of ER+ and ER−ve breast cancer cells to form tumours in bone. We have carried out detailed analysis of bone and tumour growth following administration of ZOL to mice supplemented with estradiol compared to control, to investigate the anti-tumour effects of ZOL in a high oestrogen environment. As expected, ER+ve breast cancer cells required addition of oestrogen to grow and metastasise to bone. Importantly, this study provides the first evidence that growth of ER+ve and ER−ve breast cancer cells in bone is stimulated by different mechanisms: ER+ve cells require active bone turnover but do not need increased osteoclasts activity, whereas ER−ve cells require stimulation of osteoclastic resorption of bone to grow in this environment. Furthermore, inhibition of bone turnover by ZOL reduced spontaneous metastasis of ER+ve breast cancer cells from the mammary fat pad to bone as well as dissemination and growth of ER+ve tumour cells in bone.
Materials and methods
Human breast cancer cells, MDA-MB-231-luc2 tdTomato (Calliper Life Sciences, Cheshire, UK), MCF7 and T47D (European Collection of Cell Cultures, Wiltshire, UK) were stably transfected with luc-2 using lentiviral transfection systems (Promega, Life sciences). Prior to in vivo inoculation cells were incubated for 15 min with 25 µM of 1,1′-Dioctadecyl-′,3′-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate (DiD) (Life Technologies, Paisley, UK). Tumour growth was monitored using an IVIS (luminol) system (Calliper Life Sciences). Human osteoblast-like HS5 cells were obtained from European Collection of Cell Cultures. All cell types were maintained in DMSO supplemented with 10 % FCS (Gibco, Paisley, UK).
Analysis of pro-metastatic parameters in vitro
All experiments were carried out in triplicate and repeated three times. Preliminary experiments were carried out to find optimum serum concentrations for obtaining cell growth at conditions 50 % of their maximum rate and this dose was used for cell proliferation experiments. Effects of PBS (control), 25, 50 or 100 μM ZOL on proliferation of HS5, MCF7 and T47D cells was performed in DMSO supplemented with 5 % FCS monitored every 24 h for 96 h by cell counting with a 1/400 mm2 haemocytometer (Hawksley, UK). Migration and invasion of MCF7 and T47D cells treated with ZOL/or towards HS5 cells treated with ZOL, PBS or 10 μg/ml mitomycin C (control) was assessed using 6 mm Transwell® plates with an 8.0 μm pore size (Costar, Corning Incorporated, USA) uncoated or coated with matrigel (Invitrogen). MCF7 or T47D cells were seeded into the inner chamber at a density of 5 × 105 per assay in DMSO supplemented with 2.5 % FCS and HS5 cells in DMSO supplemented with 2.5 % FCS treated with 15 μM ZOL, PBS or 10 μg/ml mitomycin C (control) added to the outer chamber. 24 after seeding cells were removed from the top surface of the membrane and cells that had invaded through the pores were stained with Haematoxylin and Eosin. Invasion was calculated as the percentage of cells that invaded through matrigel compared with cells that moved to the underside of uncoated plates Numbers of cells were counted using a DMRB microscope (Leitz, Germany) and OsteoMeasure XP v188.8.131.52 program (Osteometrics, USA).
In vivo studies
We used 12-week-old female BALB/c nude mice (Charles River, Kent, UK). Experiments were carried out in accordance with local guidelines and with Home Office approval under project licence 40/3462, University of Sheffield, UK.
For experiments investigating the effects of estradiol on ER+ve tumour growth and bone metastasis 17β estradiol pellets (Innovative Research of America) were implanted sub-cutaneously into 6 mice and 6 mice were sham operated (control). 3 days later, 5 × 105 MCF7 or T47D cells in 20 μL (50 % matrigel (BD Biosciences) 50 % PBS) were injected into the left and right hind fat pads. This experiment was repeated twice to ensure reproducibility of our model.
To investigate the effects of ZOL on primary tumour growth and bone metastasis, 5 × 105 T47D cells or MDA-MB-231 cells were injected into the left and right hind mammary fat pads 3 days after implantation of an estradiol pellet. 100 μg/kg ZOL [(1-hydroxy-2- (1H-imidazol-1-yl) ethylene) bisphosphonic acid] (Novartis Pharma AG, Basel, Switzerland) or PBS control was administered via intra-peritoneal injection (n = 8 mice/group). Primary tumour growth was measured twice per week using callipers (tumour volume = 4/3 πr3, where radius was calculated as (tumour length + width)/4), bone metastases were monitored by in vivo luciferase imaging and final tumour volume was measured on 2 non-serial histological samples taken from the right tibiae using a Leica RMRB upright microscope and OsteoMeasure software (Osteometrics, Inc. Dacatur, GA. USA.). 15 additional mice were used to study the effects of estradiol and ZOL on bone turnover. Estradiol pellets were implanted subcutaneously into 10 mice and 5 were non-estradiol control. 3-days after implantation of the pellet, 5 mice were injected once per week with 100 μg/kg ZOL the other 5 received PBS control for 4-weeks. Mice were sacrificed 24 h after their final injection with ZOL/PBS.
For investigating the effects of estradiol on dissemination and growth of ER−ve tumour cells in bone, 17β estradiol pellets were implanted sub-cutaneously into 8 mice and 8 mice were sham operated (control). 3 days following implantation of estradiol pellet/sham operation 5 × 105 MDA-MB-231 cells were injected into the left cardiac ventricle and bone metastases were monitored twice per week by luciferase imaging. Animals were sacrificed 4 weeks following injection of tumour cells.
All mice were culled by cardiac exsanguination and cervical dislocation. Whole blood was stored in heparin/10 % DMSO at −80 °C for subsequent analysis of circulating tumour cells. Serum was stored at −80 °C, primary tumours were fixed in 4 % paraformaldehyde and tibiae and femurs were fixed in 4 % PFA for μCT analysis before decalcification in 1 % PFA/0.5 % EDTA and processing for histology. Bones for two-photon analysis were stored in OCT at −80 °C.
Serum concentrations of TRAP 5b and P1NP were measured using commercially available ELISA kits: MouseTRAP™ Assay (Immunodiagnostic systems) and Rat/Mouse P1NP competitive immunoassay kit (Immunodiagnostic Systems), respectively.
Microcomputed tomography imaging
Microcomputed tomography analysis was carried out using a Skyscan 1172 X-ray-computed microtomography scanner (Skyscan, Aartselar, Belgium) equipped with an X-ray tube (voltage, 49 kV; current, 200 μA) and a 0.5-mm aluminium filter. Pixel size was set to 5.86 μm and scanning initiated from the top of the proximal tibia as previously described .
Osteoclasts were detected by toluidine blue and tartrate-resistant acid phosphatase (TRAP) staining as previously described . Osteoblasts were identified as mononuclear, cuboidal cells residing in chains along the bone surface. The number of osteoclasts/osteoblasts per millimetre of cortical-endosteal bone surface and trabecular bone surfaces and the proportion of bone surface occupied by osteoclasts/osteoblasts was determined using a Leica RMRB upright microscope and OsteoMeasure software (Osteometrics inc.) as previously described .
Tibiae were imaged using a multiphoton confocal microscope (LSM510 NLO upright; Zeiss, Cambridge, UK). DiD labelled cells were visualised using a 900 nm Chameleon laser, bone was detected using the 633 nm multiphoton laser (Coherent, Santa Clara, CA.) and images were reconstructed in LSM software version 4.2 (Zeiss). Velocity 3D image analysis software (Zeiss) was used to count the number of disseminated tumour cells in 2104 μm (X-axis) × 2525 μm (Y-axis) × 100 μm (Z-axis) of the left proximal tibia just below the growth plate.
Isolation of circulating tumour cells
Whole blood was analysed from each of the 8 mice per treatment group and parental MCF7 cells were used for staining controls using the protocol described in Holen et al. , with the exception that the primary antibody used was anti-human EpCAM antibody directly conjugated to Phycoerythrin (PE) (Clone 1B7; 1:50; eBioscience, Hatfield, UK). PE positive cells were plated directly into a 96-well tissue culture plate on a MoFlow High performance cell sorter (Beckman Coulter, Cambridge, UK). PE fluorescence was detected by a 555LP dichroic long pass and a 580/30 nm band pass filter. Acquisition and analysis of cells was performed using Summit 4.3 software. Following sorting, cells were cultured in RPMI medium supplemented with 10 % FCS.
Linear regression was calculated for ‘slope significance to non zero’ using R2 and Syx tests. For Kaplan–Meier survival charts, statistical analysis was by one tailed Mantel–Haenszel test and log rank test for trend. All other statistical analysis was by one way analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison test. Data for in vivo experiments are shown as mean ± SD and for in vitro experiments as mean ± SEM. Statistical significance was defined as P ≤ 0.05 as calculated using Graphpad PRISM software. All P values are two-sided.
ER+ve breast cancer cells metastasise to bone from the mammary fat pads
Estradiol does not stimulate growth of ER−ve breast cancer cells in bone
ZOL inhibits metastasis of T47D cells to bone from tumours in the mammary fat pad
Effects of ZOL on ER+ve circulating and disseminated tumour cells
Effects of estradiol and ZOL on bone
Effects of bone cells ± ZOL on migration and invasion of ER+ve breast cancer cells
To date, only a small number of studies have been carried out investigating the effects of ZOL on ER+ve breast cancer and parameters associated with metastasis. These have focused on in vitro models of tumour apoptosis [20, 21] proliferation [22, 23], migration [24, 25] and invasion [25, 26] and until now there has been no data available from clinically relevant in vivo models representing metastasis of human breast cancer cells from the primary site to bone. For the current study we have used MCF7 and T47D cells to establish in vivo models of ER+ve breast cancer bone metastasis. Injection of either MCF7 or T47D cells into the two hind mammary fat pads of 12-week old BALB/c nude mice, 3 days after subcutaneous implantation of a slow release estradiol pellet, resulted in spontaneous overt metastasis detected exclusively in long bones of the hind limbs within 2–3 weeks. All animals supplemented with estradiol were sacrificed before control mice and before the pre-planned protocol endpoint due to loss of 10 % of body mass. Although the size primary tumours in estradiol supplemented animals were small (135 ± 25.5 mm3 for T47D and 126 ± 29.46 mm3 for T47D) and did not differ significantly from primary tumours in control mice estradiol supplemented animals had the additional burden of bone metastases. It is likely that this additional tumour burden contributed to accelerated loss of body mass seen in these animals. Mice bearing T47D tumours remained healthier for longer and therefore these models were used for subsequent in vivo experiments. Using these models, we have shown that administration of a clinically relevant dose of ZOL (100 μg/kg, equivalent to the 4 mg clinical dose) once per week reduces the number of tumour cells that disseminate into the bone environment and inhibits development of bone metastases. We did not detect overt metastasis by luciferase imaging in any other bony sites or soft tissue during the 56 day protocol. However, we did not perform two-photon analysis in tissues other than tibiae and femurs and therefore further experiments need to be carried out into accurately characterise the metastatic potential of MCF7 and T47D cells in these models.
Our present data suggest that the direct effects of ZOL on tumour cell proliferation in vitro and in soft tissue tumours in vivo are similar for both ER+ve and hormone receptor negative breast cancer cells. Numerous reports show direct anti-proliferative effects of adding 5–25 μM ZOL to the media of ER+ve MCF7 and T47D cells as well as hormone receptor negative MDA-MB-231 and MDA-MB-436 cells [reviewed in 27, 28]. In the current study we wanted to mimic the effects of ZOL in the bone environment. ZOL has high affinity of calcium in bone where it is preferentially incorporated into sites of active bone remodelling. In breast cancer patients, this results in millimolar concentrations of ZOL accumulating in bone following a single 4 mg infusion  and 60–65 % of this is retained by the skeleton . As ZOL is directly incorporated into the skeleton, this compound has long lasting effects in this organ and it is estimated that the concentration of bisphosphonates in the resorption lacuna can be up to 10–1000 μM . We therefore investigated the effects of 25–100 μM ZOL tumour cell proliferation, migration and invasion towards HS5 bone cells. In agreement, our current data show that exposure to 25 μM ZOL inhibits proliferation of MCF7 and T47D cells. There are no published data relating to the direct anti-tumour effects of ZOL on ER+ve soft tissue tumours, however, we and others have consistently shown that administration of clinically relevant doses of ZOL do not exert anti-tumour effects on ER−ve soft tissue tumours in vivo [32, 33, 34, 35]. Similarly, the current study demonstrated an absence of anti-tumour activity against ER−ve MDA-MB-231 or ER+ve MCF7 mammary tumours following weekly administration of 100 μg/kg ZOL in vivo. It therefore seems likely that concentrations of ZOL that reach soft tissue tumours in vivo are not sufficient to affect tumour growth and any anti-metastatic effects are unlikely to be as a result of ZOL acting directly on the primary tumour.
ZOL is shown to inhibit migration and invasion of ER−ve breast cancer cells but has comparatively modest inhibitory effects on ER+ve cells in vitro [36, 37, 38]. In agreement with this, we found no effects of ZOL on migration or invasion of MCF7 or T47D cells in vitro (data not shown). However, addition of either the cytostatic compound mitomycin C, or 25 μM ZOL, to a transwell assay inhibited HS5 (bone cell) stimulated migration and invasion of MCF7 and T47D cells, suggesting that repressing proliferation of bone cells inhibits metastatic potential of ER+ve breast cancer cells. This hypothesis was supported by our in vivo studies, in which we found a trend towards decreased numbers of tumour cells being disseminated from primary T47D mammary tumours into the blood stream of mice treated with ZOL compared with control (saline) treated mice (P = 0.056). This was accompanied by a significant decrease in the numbers of DiD-labelled tumour cells in the tibiae of mice treated with estradiol and ZOL, compared with mice treated with estradiol alone. We can not decipher whether lower numbers of disseminated DiD-labelled tumour cells in bone are as a result of fewer available cells in the circulation that could colonise this site, or whether ZOL induced alterations to the bone microenvironment make bone less permissive for ER+ve tumour cell homing and/or colonisation. Interestingly, we have recently shown that a single dose of ZOL does cause substantial alterations to the areas of the tibia most commonly colonised by breast cancer cells in BALB/c nude mice . Although this caused a re-distribution of ER−ve cancer cells in bone, the total number of tumour cells was unaffected. However, the model used by Haider et al. relies on tumour cells being injected directly into the circulation and therefore does not represent the effects of ZOL on tumour cell dissemination in bone from a primary site. It must be noted that extrapolation of numbers of tumour cells disseminated in bone by counting DiD labelled cells is likely to be an underestimate. DiD is a lipophilic membrane dye that is retained by non-proliferating cells and lost as tumour cells divide . ZOL significantly inhibited formation of tumours in bone, therefore more tumour cells that have disseminated in bone will retain DID in the ZOL treated group at the 4 week time point measured, compared with control where proliferating tumour cells will gradually lose the dye and become undetectable. Whether tumours develop in bone from one or several disseminated tumour cells remains an unanswered question, making it difficult to judge the extent to which this affects our analysis. It is likely that ZOL induced reduction in numbers of tumour cells that disseminate in bone contribute to the reduced tumour burden observed in ZOL treated animals compared with control, however, this is probably not the only mechanism. We have previously shown that administration of ZOL or OPG-Fc prevents OVX-induced growth of dormant breast cancer cells to form overt tumours in bone, demonstrating that inhibition of activity of bone cells prevents proliferation of disseminated tumour cells in this environment [16, 17]. It is possible that some antitumour effects of ZOL remain unaccounted for in our model. We have used athymic nude mice that lack T-cells to allow the growth and metastasis of human cancer cell lines. There is accumulating evidence suggesting that ZOL has immunomodulatory properties that may contribute to the potential anti tumour effects of this compound [39, 40, 41]. Unfortunately, there is no immunocompetent model of ER+ve breast cancer metastasis to bone that will allow us to study this in more detail, further highlighting the need for the development of more clinically relevant in vivo models.
Castration-induced bone loss and PTH induced increase in osteoclasts and osteoblasts stimulate MDA-MB-231 tumour growth in bone [16, 17]. The compensatory mechanisms coupling activity of osteoclasts and osteoblasts makes it difficult to distinguish which cell type is involved in stimulation of tumourigenesis. In order for MCF7 or T47D cells to metastasise to bone it was necessary to increase the concentrations of circulating oestrogen in the mice by implanting a slow release estradiol pellet. Oestrogen has well defined activity in bone causing apoptosis in osteoclasts whilst prolonging the life of osteoblasts [8, 9, 10, 11, 12, 13] and analysis of serum and bones from animals given estradiol supplementation revealed substantial increases in osteoblast activity but no significant alterations in osteoclast activity. This is in agreement with our previous data showing increased numbers of osteoblasts and no alterations in numbers of osteoclasts in bones from animals supplemented with estradiol . We therefore investigated whether these oestrogen-mediated alterations in bone turnover were responsible for stimulating tumour growth in bone. Injection of hormone receptor negative MDA-MB-231 cells directly into the circulation of 12-week old mice supplemented with estradiol resulted in tumour cells disseminating in bone, but did not stimulate tumour formation, suggesting that MDA-MB-231 cells require osteoclast mediated bone resorption to proliferate in the bone environment of adult mice. In contrast, ER+ve cells readily form tumours in this estradiol high and osteoblast rich environment, but are not stimulated to proliferate in bone under conditions of increased bone resorption . Administration of ZOL to mice supplemented with estradiol resulted in significant decrease in osteoclast activity and restored osteoblast activity to background (control) levels (Fig. 3c, d). It therefore appears that either ER+ve breast cancer cells require increased osteoblast activity to grow in bone, or they can grow in bone under normal conditions of bone resorption (requiring estradiol as a growth factor independent of the bone environment). Our data suggest that decreased bone turnover following ZOL prevents proliferation of disseminated ER+ve cells in bone, however, the mechanism behind this has yet to be fully established. Further studies are now required to decipher which cell types are important for ER+ve tumour growth in bone and why ZOL appears to have reduced capacity to inhibit osteoblast activity in a high oestrogen environment.
In conclusion, ZOL exerts indirect and direct effects that inhibit spontaneous bone metastasis from ER+ve mammary tumours. Administration of ZOL does not alter growth of ER+ve cells at the primary site but reduces tumour cell dissemination in bone. Once cells have disseminated in the bone environment the ZOL-mediated reduction in bone turnover prevents tumour cells from proliferating and forming overt metastases. The mechanism for stimulating tumour growth in bone appears to be different for hormone receptor negative and ER+ve breast cancer cells; hormone receptor negative cells require increased bone resorption to proliferate and form bone metastases whereas ER+ve cells do not. As both hormone receptor negative and ER+ve breast cancer cells require active bone resorption for tumours to grow in this environment, we hypothesise that ZOL inhibits tumour growth in bone form both types of breast cancer by inhibiting bone turnover. It is therefore likely that ZOL has more potent effects on tumour growth in patients who are 5-years or more post menopause as firstly these patients exhibit higher levels of bone turnover at baseline than pre-menopausal patients and therefore gain more benefit from anti-resorptive therapy  and secondly, ZOL appears to have increased ability to reduce bone turnover in a low oestrogen environment.
The IVIS Lumina II system was purchased by an equipment grant from Yorkshire Cancer Research. Laboratory consumables were paid from by grants from Cancer Research UK and Weston Park Hospital Cancer Charity, UK.
IH- study design and manuscript editing, MW– in vitro data acquisition and analysis and in vivo data analysis, FN- ER+ve in vivo data acquisition and analysis, AF- ER−ve in vivo data acquisition and analysis, AE- in vitro data acquisition and analysis, CE– study design and manuscript editing and PO- conceived the study, data analysis and manuscript preparation.
Compliance with ethical standards
Conflict of interest
Authors have no competing interests to declare.
- 4.Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) AZURE investigators. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006CrossRefPubMedGoogle Scholar
- 17.Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL, Holen I (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer. (Epub ahead of print)Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.